RT Journal Article
T1 Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study.
A1 Valdizán-Usón, J R
A1 Cánovas-Martínez, A
A1 Lucas-Taracena, M T de
A1 Díaz-Atienza, F
A1 Eddy-Ives, L S
A1 Fernández-Jaén, A
A1 Fernández-Pérez, M
A1 García-Giral, M
A1 García-Magán, P
A1 Garraus-Oneca, M
A1 Idiazábal-Alecha, M A
A1 López-Benito, M
A1 Lorenzo-Sanz, G
A1 Martínez-Antón, J
A1 Martínez-Granero, M A
A1 Montañés-Rada, F
A1 Mulas-Delgado, F
A1 Ochando-Perales, G
A1 Ortega-García, E
A1 Pelaz-Antolín, A
A1 Ramos-Quiroga, J A
A1 Ruiz-Sanz, F C
A1 Vaquerizo-Madrid, J
A1 Yusta-Izquierdo, A
K1 Attention deficit hyperactivity disorder
K1 ADHD
K1 Pharmacologic treatment
K1 Methylphenidate
K1 Satisfaction
K1 Metilfenidato
K1 Trastorno por Déficit de Atención con Hiperactividad
K1 Estudios Multicéntricos como Asunto
K1 España
K1 Niño
K1 Adulto
AB BACKGROUNDThe purpose of this multicenter Spanish study was to evaluate the response to immediate-release methylphenidate by children and adults diagnosed with attention-deficit/hyperactivity disorder (ADHD), as well as to obtain information on current therapy patterns and safety characteristics.METHODSThis multicenter, observational, retrospective, noninterventional study included 730 patients aged 4-65 years with a diagnosis of ADHD. Information was obtained based on a review of medical records for the years 2002-2006 in sequential order.RESULTSThe ADHD predominantly inattentive subtype affected 29.7% of patients, ADHD predominantly hyperactive-impulsive was found in 5.2%, and the combined subtype in 65.1%. Overall, a significant lower Clinical Global Impression (CGI) score and mean number of DSM-IV TR (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision) symptoms by subtype were found after one year of treatment with immediate-release methylphenidate; CGI decreased from 4.51 to 1.69, symptoms of inattention from 7.90 to 4.34, symptoms of hyperactivity from 6.73 to 3.39, and combined subtype symptoms from 14.62 to 7.7. Satisfaction with immediate-release methylphenidate after one year was evaluated as "very satisfied" or "satisfied" by 86.90% of the sample; 25.75% of all patients reported at least one adverse effect. At the end of the study, 41.47% of all the patients treated with immediate-release methylphenidate were still receiving it, with a mean time of 3.80 years on therapy.CONCLUSIONGood efficacy and safety results were found for immediate-release methylphenidate in patients with ADHD.
PB Dove Medical Press
YR 2013
FD 2013-02-08
LK http://hdl.handle.net/10668/1447
UL http://hdl.handle.net/10668/1447
LA en
NO Valdizán-Usón JR, Cánovas-Martínez A, De Lucas-Taracena MT, Díaz-Atienza F, Eddy-Ives LS, Fernández-Jaén A, et al. Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study. Neuropsychiatr Dis Trea. 2013; 9:218
NO Journal Article;
DS RISalud
RD Apr 19, 2025